Treatment of metastatic breast cancer: Looking towards the future

Breast Cancer Research and Treatment

Volumn 114, Issue 3, 2009, Pages 413-422

  Amar, Surabhi ^a   Roy, Vivek ^a   Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bevacizumab; Docetaxel; Lapatinib; Metastatic breast cancer; Paclitaxel; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CREMOPHOR; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; IXABEPILONE; LAPATINIB; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ANTIANGIOGENIC ACTIVITY; BLOOD TOXICITY; BONE MARROW TOXICITY; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DRUG INDICATION; FATIGUE; HUMAN; HYPERSENSITIVITY REACTION; LOADING DRUG DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SENSORY NEUROPATHY; STANDARD; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; PACLITAXEL; QUINAZOLINES; TAXOIDS; TREATMENT OUTCOME;

EID: 61449222107     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0032-3     Document Type: Review

References (55)

1. H Mouridsen M Gershanovich Y Sun 2003 Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 21 11 2101 2109
2. JM Nabholtz J Bonneterre A Buzdar 2003 Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results Eur J Cancer 39 12 1684 1689
3. JM Nabholtz A Buzdar M Pollak 2000 Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group J Clin Oncol 18 22 3758 3767
4. G Batist G Ramakrishnan CS Rao 2001 Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer J Clin Oncol 19 5 1444 1454
5. L Harris G Batist R Belt 2002 Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma Cancer 94 1 25 36
6. AK Conlin AD Seidman 2007 Taxanes in breast cancer: an update Curr Oncol Rep 9 1 22 30
7. Seidman A, Berry D, Cirrincione C et al (2004) CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 22(14S); Abstract 512
8. V Harvey H Mouridsen V Semiglazov 2006 Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer J Clin Oncol 24 31 4963 4970
9. TA John SM Vogel C Tiruppathi 2003 Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer Am J Physiol 284 1 L187 L196
10. WJ Gradishar D Krasnojon S Cheporov 2006 A randomized phase 2 trial of qw or q3w ABI-007 (ABX) vs. q3w solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC) Breast Cancer Res Treat 100 Suppl 1 S21 Abstract 46
11. O'Shaughnessy J, Nag S, Calderillo-Ruiz G et al (2003) Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracylcine pretreated metastatic breast cancer (MBC): interim results of a global phase III study. Proc Am Soc Clin Oncol 22; Abstract 25
12. D Miles S Vukelja V Moiseyenko 2002 Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 2812 2823
13. Albain K, Nag S, Calderillo-Ruiz G et al (2004) Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. J Clin Oncol 22(14S); Abstract 510
14. D Miles S Vukelja V Moiseyenko 2004 Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial Clin Breast Cancer 5 4 273 278
15. GW Sledge D Neuberg P Bernardo 2003 Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) J Clin Oncol 21 4 588 592
16. E Alba M Martin M Ramos 2004 Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study J Clin Oncol 22 13 2587 2593
17. E Baldini T Prochilo B Salvadori 2004 Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety Brit J Cancer 91 1 45 49
18. S Cresta G Grasselli M Mansutti 2004 A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer Ann Oncol 15 3 433 439
19. ES Thomas HL Gomez RK Li 2007 Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 25 33 5210 5217
20. EA Perez G Lerzo X Pivot 2007 Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine J Clin Oncol 25 23 3407 3414
21. DJ Slamon B Leyland-Jones S Shak 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 New Engl J Med 344 783 792
22. M Marty F Cognetti D Maraninchi 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 4265 4274
23. M Marty F Cognetti D Maraninchi 2006 Superior long-term survival benefits of trastuzumab plus docetaxel compared to docetaxel alone in patients with HER2-positive metastatic breast cancer: patients surviving more than 4 years in the M77001 study Breast Cancer Res Treat 100 Suppl 1 S103 Abstract 2067
24. MD Pegram T Pienkowski DW Northfelt 2004 Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer J Natl Cancer Inst 96 759 769
25. Slamon D, Yeon CH, Pienkowski T et al (2004) Survival analysis from two open-label non-randomized phase II trials of trastuzumab (H) combined with docotaxel (T) and platinums (C, cisplatin or carboplatin) (TCH) in women with HER2+ advanced breast cancer (ABC). J Clin Oncol 22(14S); Abstract 642
26. H Burris 3rd D Yardley S Jones 2004 Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer J Clin Oncol 22 1621 1629
27. EA Perez VJ Suman KM Rowland 2005 Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252 Clin Breast Cancer 6 425 432
28. N Robert B Leyland-Jones L Asmar 2006 Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer J Clin Oncol 24 2786 2792
29. M Pegram J Forbes T Pienkowski 2007 BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC) J Clin Oncol 25 18S 968S Abstract LBA1008
30. Mackey J, Kaufman B, Clemens M et al (2006) Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat 100(Suppl 1):S5; Abstract 3
31. CE Geyer J Forster D Lindquist 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer New Engl J Med 355 26 2733 2743
32. T Force DS Krause RA Van Etten 2007 Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition Nat Rev 7 5 332 344
33. R Kerkela L Grazette R Yacobi 2006 Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nat Med 12 8 908 916
34. E Perez J Byrne I Hammond 2006 Cardiac safety experience in 3127 patients (pts) treated with lapatinib Ann Oncol 17 Suppl 9 ix70 Abstract 1420
35. F Ciardiello R Caputo R Bianco 2000 Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor Clin Cancer Res 6 2053 2063
36. SX Yang RM Simon AR Tan 2005 Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer Clin Cancer Res 11 6226 6232
37. F Ciardiello T Troiani F Caputo 2006 Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer Brit J Cancer 94 1604 1609
38. EA Rakha DA El-Rehim C Paish 2006 Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance Eur J Cancer 42 18 3149 3156
39. S Banerjee JS Reis-Filho S Ashley 2006 Basal-like breast carcinomas: clinical outcome and response to chemotherapy J Clin Pathol 59 7 729 735
40. SR Lakhani JS Reis-Filho L Fulford 2005 Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype Clin Cancer Res 11 14 5175 5180
41. S Modi G D'Andrea L Norton 2006 A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer Clin Breast Cancer 7 3 270 277
42. MA Cobleigh VK Langmuir GW Sledge 2003 A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer Semin Oncol 30 117 124
43. CJ Sweeney KD Miller SE Sissons 2001 The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors Cancer Res 61 3369 3372
44. KD Miller LI Chap FA Holmes 2005 Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 792 799
45. K Miller M Wang J Gralow 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer New Engl J Med 357 26 2666 2676
46. B Ramaswamy AD Elias NT Kelbick 2006 Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients Clin Cancer Res 12 3124 3129
47. Perez EA, Hillman DW, Kugler JW et al (2006) North Central cancer treatment group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Breast Cancer Res Treat 100(Suppl 1); Abstract 2069
48. JS Link JR Waisman CI Jacobs 2006 Bevacizumab (avastin) and albumin bound paclitaxel (abraxane) treatment in metastatic breast cancer Breast Cancer Res Treat 100 Suppl 1 S69 Abstract 1095
49. G Sledge K Miller C Moisa W Gradishar 2007 Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer J Clin Oncol 25 18S 35S Abstract 1013
50. HB Muss LD Case F Richards 2nd 1991 Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association New Engl J Med 325 19 1342 1348
51. A Gennari D Amadori M De Lena 2006 Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer J Clin Oncol 24 24 3912 3918
52. A Coates V Gebski JF Bishop 1987 Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies New Engl J Med 317 24 1490 1495
53. GE Konecny YG Meng M Untch 2004 Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients Clin Cancer Res 10 5 1706 1716
54. M Pegram D Chan RA Dichmann 2006 Phase II combined biological therapy targeting the HER2-proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HEr2-amplified breast cancer Breast Cancer Res Treat 100 Suppl 1 S28 Abstract 301
55. Gomez H, Chavez M, Doval D et al (2005) A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. J Clin Oncol 23(16S); Abstract 3046